PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Dirozalkib Halves Progression Risk Versus Crizotinib in First-Line ALK-Positive NSCLC

dirozalkibcrizotinibALK inhibitorALK-positive NSCLCnon-small-cell lung cancerfirst-linebrain metastasesphase III randomized trialtyrosine kinase inhibitoroncology pharmacy Oncology Pharmacy

Background Information

Dirozalkib shows superior efficacy to crizotinib in ALK-positive NSCLC.

Dirozalkib offers a promising first-line treatment for ALK-positive non-small-cell lung cancer (NSCLC), especially for patients with brain metastases. Median progression-free survival (PFS) was 29.5 months for dirozalkib compared to 12.9 months for crizotinib, with fewer severe adverse events. Dirozalkib could become a preferred first-line option for ALK-positive NSCLC due to its superior efficacy and safety profile. Confirmatory real-world data are needed. Dirozalkib outperforms crizotinib in ALK-positive NSCLC, with improved PFS and tolerability.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Liu Y, Meng X, Yu Y, Chen J, Yang R, Liu L, Zhao Y, Tian R, Li D, Ning R, Li Q, Wu G, Wang L, Duan X, Guo X, Hu Y, Liu W, Liu H

Citation: Liu Y, Meng X, Yu Y, et al. Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial. Cancer communications (London, England). 2026;46:0068. doi:10.34133/cancomm.0068

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.